Table 2.
β-lactamases activity.
| WT | PENI | ESBL | CEPH | CARBA | |||
|---|---|---|---|---|---|---|---|
| WT | TEM PSE CARB | OXA | PER VEB TEM SHV CTX-M | OXA | AmpC | IMP VIM NDM KPC | |
| Carboxypenicillins | S | R | R | R | R | R | R |
| Carboxypenicillins +BLI | S | S/I | I/R | S/I | I/R | R | R |
| Ureidopenicillins | S | I/R | R | I/R | R | I/R | R |
| Ureidopenicillins +BLI | S | S/I | I/R | S/I | I/R | I/R | R |
| Ceftazidime | S | S | S | R | I/R | I/R | R |
| Cefepime | S | S | I/R | R | I/R | I/R | R |
| Aztreonam | S | S | S | R | I/R | I/R | S |
| Imipenem | S | S | S | S | S | S | R |
BLI, β-lactamase inhibitor; CARBA, carbapenemase; CEPH, cephalosporinase AmpC; ESBL, extended-spectrum β-lactamase; I, intermediate resistance; PENI, penicillinase; R, resistance; S, susceptible; WT, wild type.